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Abstract
Background: The ubiquitous transcription factor Sp1 regulates the expression of a vast number of genes involved in many
cellular functions ranging from differentiation to proliferation and apoptosis. Sp1 expression levels show a dramatic increase
during transformation and this could play a critical role for tumour development or maintenance. Although Sp1
deregulation might be beneficial for tumour cells, its overexpression induces apoptosis of untransformed cells. Here we
further characterised the functional and transcriptional responses of untransformed cells following Sp1 overexpression.
Methodology and Principal Findings: We made use of wild-type and DNA-binding-deficient Sp1 to demonstrate that the
induction of apoptosis by Sp1 is dependent on its capacity to bind DNA. Genome-wide expression profiling identified genes
involved in cancer, cell death and cell cycle as being enriched among differentially expressed genes following Sp1
overexpression. In silico search to determine the presence of Sp1 binding sites in the promoter region of modulated genes
was conducted. Genes that contained Sp1 binding sites in their promoters were enriched among down-regulated genes.
The endogenous sp1 gene is one of the most down-regulated suggesting a negative feedback loop induced by
overexpressed Sp1. In contrast, genes containing Sp1 binding sites in their promoters were not enriched among up-
regulated genes. These results suggest that the transcriptional response involves both direct Sp1-driven transcription and
indirect mechanisms. Finally, we show that Sp1 overexpression led to a modified expression of G1/S transition regulatory
genes such as the down-regulation of cyclin D2 and the up-regulation of cyclin G2 and cdkn2c/p18 expression. The biological
significance of these modifications was confirmed by showing that the cells accumulated in the G1 phase of the cell cycle
before the onset of apoptosis.
Conclusion: This study shows that the binding to DNA of overexpressed Sp1 induces an inhibition of cell cycle progression
that precedes apoptosis and a transcriptional response targeting genes containing Sp1 binding sites in their promoter or
not suggesting both direct Sp1-driven transcription and indirect mechanisms.
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Introduction
Transcription factor Sp1 was the first identified member of the
Sp/XKLF (Specificity protein/Kru ¨ppel-like factor) family. Sp1
protein comprises several domains of which the DNA binding
domain is the most conserved among Sp family. The DNA
binding domain of Sp1 consists of three contiguous Cys2His2 Zinc
(Zn) fingers and mutational analysis has revealed that Zn fingers 2
and 3 are essential for Sp1 DNA binding activity [1]. Sp1 binds
GC-rich elements [2] that are common regulatory elements in
promoters of numerous genes. Sp1 binds individual Sp1 binding
sites as a multimer and is capable of synergic activation on
promoters containing multiple binding sites [3]. Sp1 regulates
transcription by dynamically recruiting and forming complexes
with many factors associated with transcription [4]. Although Sp1
has been described as a transcriptional activator it can also act as a
repressor. Activation or repression of transcription by Sp1 depends
on the promoter it binds to and on the co-regulators it interacts
with [5].
An unbiased mapping of in vivo occupied Sp1 binding sites by
combining chromatin immunoprecipitation and oligonucleotides
arrays has led to the estimation that the human genome contains
at least 12,000 Sp1 binding sites [6]. Therefore it is not surprising
that Sp1 has been implicated in the expression of numerous genes
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growth, differentiation, angiogenesis and apoptosis regulation.
Although Sp1 is widely expressed and binds the promoters of a
large number of genes, it is involved in tissue specific gene
expression, its activity being finely modulated by a variety of
stimuli through multiple post-translational modifications [7].
Sp1 expression levels are also regulated, changes in its
expression levels being observed during murine development
and during transformation. Indeed, differences in the levels of Sp1
of up to 100 times were observed during the development and the
differentiation of mouse organs [8]. Importantly, Sp1 expression is
increased in a number of tumour cells and this could be a critical
factor for tumour development or maintenance. Indeed, Sp1 levels
and/or activities are increased in gastric cancer, breast carcinoma
and pancreatic carcinoma compared with normal tissues [1,9,10].
This elevated Sp1 expression is inversely correlated with the
survival of patients with gastric cancer [9]. In primary pancreatic
adenocarcinoma Sp1 overexpression identifies advanced stage
tumours and predicts a poor clinical outcome [11]. Moreover, Sp1
levels slowly increase during mice skin tumour progression [12]
and Sp1 accumulates in N-methyl-N-nitrosourea-induced mam-
mary tumour cells compared to normal mammary cells [13]. Sp1
levels also increase during the process of transformation in a
fibrosarcoma transformation model and reducing Sp1 expression
in those human transformed fibroblasts inhibits their tumorogeni-
city [14]. Moreover reduction of Sp1 expression in pancreatic
cancer cells inhibit their growth and metastasis in mouse models
[15]. Sp1 could contribute to transformation via the regulation of
expression of genes regulating cell growth (c-jun, Raf, cyclins, cdk
inhibitors, E2F1, TGF-b, IEX-1 and TCL1), apoptosis (Bcl-2)o r
angiogenesis (VEGF, FGF) [16,17]. Altogether, these findings show
that Sp1 is overexpressed or overactivated in a number of cancers
and that its activity plays a role in late stage of carcinogenesis.
Although Sp1 deregulation might be beneficial for tumour cells,
we and others have previously shown that deregulation of Sp1
expression on its own induces apoptosis of several untransformed
cell lines [18,19]. The aim of the study was to further characterise
the functional and transcriptional responses of untransformed cells
following Sp1 overexpression. We used wild-type and DNA-
binding-deficient Sp1 to demonstrate that Sp1-induction of
apoptosis in untransformed Baf-3 cells requires its binding to
DNA. Genome-wide expression profiling showed that Sp1
overexpression induces a transcriptional response that is enriched
for genes regulating cell death and cell cycle. Sp1 overexpression
leads to the down-regulation of cyclin D2 expression and the up-
regulation of cyclin G2 and cdkn2c expression. Moreover, we show
that this deregulation of cell cycle regulating genes is associated
with the accumulation of cells in the G1 phase of the cell cycle.
Finally, microarray data combined with promoter analysis
revealed that only a fraction of the promoters of deregulated
genes are enriched in Sp1-binding sites. This suggests that the
transcriptional response induced by overexpressed Sp1 involves
direct Sp1-driven transcription but also indirect mechanisms.
Materials and Methods
Cell culture
The murine IL-3-dependent Baf-3 cell line was maintained in
DMEM (Gibco) containing 6% FBS (Pan Biotech GmbH) and 5%
IL-3 as described [20]. Drosophila Schneider’s SL2 cells were
cultured in Drosophila medium (Invitrogen) containing 10% FBS
at 28uC [21]. Baf-3 clones expressing inducible Sp1 and GFP were
obtained as described previously [18]. To repress ectopic Sp1
expression, cells were grown in presence of doxycyline (30 ng/ml,
Sigma). To induce Sp1 and GFP expression, cells were washed 3
times and cultured without doxycyline. Among the inducible
clones generated, one expressed a truncated form of Sp1 (tSp1,
Figure 1C) due to the integration into the genome of a retrovirus
coding for a truncated Sp1 (data not shown). tSp1 is composed of
the first 418 amino acids and is devoid of DNA binding domain
and nuclear localisation sequences (Figure S1).
Retroviral constructions, transfections and transductions
The retroviruses coding for full-length human Sp1 protein
followed by an internal ribosomal entry site and a truncated cell
surface marker (CD2) to identify transduced cells were described
previously [18]. Sp1 carrying mutations of the second and third Zn
Fingers (Sp1
Zn2,3) (Figure S1) was obtained by PCR-mediated site-
directed mutagenesis using pCMX-Gal4NSp1ZFM2 vector (a kind
gift of Dr Hur MW, Seoul, Korea) encoding the DNA binding
domain (amino acids 622–720) mutated for the second Zn Finger.
Mutation of the third Zn finger was obtained using the following
oligonucleotides 59-CCTCATGAAGCGCTTAGGACTCTCAG-
GGCTGGCAAATTTCTTCTCACCTGTGTGTGTACGTTT-
GTGCCTCTGTAGCTCATCGGTGAGAAGAAATTTGCCA-
GCCCTGAGTGCCTAAG-39, BamHI site: 59-CCGCGGATC-
CTGGCAAAAAGAAACAGC-39. The BamHI/Ecor47III cDNA
PCR fragments were subcloned into pBSK-Sp1 to give pBSK-
Sp1Zn
2,3. The EcoRI-XhoI fragment was sequenced before
subcloning into pMX-IRES-CD2. Sp1, Sp1
Zn2,3 or EGFP cDNA
werecloned under the Drosophila actinAC5 promoter intopAc5.1/
V5-HisA vector (Invitrogen). The pGL2 derivative carries the tata-
Sp1 promoter [21]. Transfections, transductions, magnetic selection
of CD2-expressing cells and western blot analysis were performed as
described [18].
Luciferase assay
SL2 cells were transfected with 5 mg of tata-Sp1 reporter
plasmid and 0.5 mg of Drosophila expression vectors pPac,
pPacSp1 or pPacSp1
Zn2,3 and 0.5 mg of pPac-EGFP to quantify
transfection efficiency. 48 hrs after transfection cells were lysed in
100 ml of Reporter Lysis Buffer (Promega) for 10 min. Samples
were frozen at 280uC for at least 1 h. Luciferase assay was
performed with Luciferase Assay System (Promega). Luciferase
activity was normalized based on protein concentration (Bradford
method) and on transfection efficiency determined as percentage
of EGFP positive cells counted on a FACScalibur (Becton-
Dickinson) and analysed using the CellQuest software.
Electrophoretic mobility shift assay
Proteins Sp1 or Sp1
Zn2,3 were synthesised in vitro using a
reticulocyte coupled transcription/translation system (Promega).
The oligonucleotide probe carrying the Sp1 consensus sequence
(upper strand sequence: 59-ATTCGATCGGGGCGGGGC-
GAGC-39) was
32P end-labelled with T4 DNA polynucleotide
kinase (Promega). The binding reaction was performed in a 15 ml
volume of binding buffer containing 2.5 mlo fin vitro protein,
1.5 mg poly dI-dC and oligonucleotide probe for 30 min at room
temperature and run on a gel.
Cell viability and cell cycle analysis
Viability was measured using Fluorescein-5-isothiocyanate
(FITC)-Annexin V staining (BD Biosciences Pharmingen) or
Propidium Iodide staining (2 mg/ml, Sigma) by flow cytometry.
Cell cycle was analysed using the Flow Cytometry Kit (BD
Biosciences Pharmingen). Cells (2.10
5 cells/ml) were grown for
16 hrs and then labelled with BrdU (32 mM, 20 min). Cells were
Cell Cycle Inhibition by Sp1
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DNase (1 hr, 37uC). Cells were stained with Allophycocyanin-
conjugated anti-BrdU and 7-amino-actinomycin D (7-AAD).
When required, transduced cells were stained with Phycoery-
thrin (PE)-coupled anti-CD2 antibody (30 min, 4 mg/ml, BD
Biosciences Pharmingen). BrdU incorporation (FL4-H), 7-AAD
(FL3-H) and CD2 expression (FL2-H) were recorded using a
FACScalibur.
Immunofluorescence microscopy
Cells seeded on 12-mm glass coverslips coated with 0.01% Poly-
L-lysine (Sigma) were fixed with 4% paraformaldehyde (BDH) in
PBS for 5 min then permeabilised with 0.25% Triton X-100
(BDH) in PBS for 5 min. Sp1 was detected using anti-Sp1
polyclonal rabbit antibody (1:100, 120 min) followed by biotin-
conjugated goat anti-rabbit antibody (5 mg/ml, Jackson Immu-
noResearch, 30 min) and either FITC-conjugated streptavidin
(1 mg/ml, BD Biosciences Pharmingen, 30 min) or Tetramethyl-
Rhodamine-Iso-Thio-Cyanate (TRITC)-conjugated streptavi-
din (3 mg/ml, Jackson ImmunoResearch, 30 min). Actin was
labelled with rhodamine-conjugated phalloidin (0.2 mg/ml, Sigma,
30 min).
Detergent Triton X-100 was used to remove soluble proteins
while leaving more tightly bound protein [22]. Thirty hrs after
transduction, 10
6 cells were stained for 45 min with 0.5 mg
biotinylated anti-CD2 antibody and with 0.75 mg TRITC-conju-
gated streptavidin for 20 min (Jackson ImmunoResearch). Cells
were then washed in PBS containing 0.5 mM MgCl2 and 0.5 mM
CaCl2, incubated for 5 min in CSK buffer (10 mM Pipes-KOH,
pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2)a n d
incubatedfor3 mininCSK buffercontaining0.02%TritonX-100.
A 10 timesexcess ofCSKbuffer wasadded and cellswereloadedon
Poly-L-lysine-coated coverslips and fixed immediately with 4%
paraformaldehyde. Specimens were stained with 1:100 anti-Sp1
antibody for 2 hrs followed by Alexa488 conjugated anti-rabbit
antibody (Molecular Probes). Actin staining was performed in
parallel to confirm the efficiency of triton removal of soluble
proteins (not shown). Slides were mounted with ProLong anti-fade
(Molecular Probes) containing DRAQ5 (1:500, Alexis corporation)
to counterstain DNA. Images of cells (single sections) were obtained
using a Zeiss LSM 510 confocal laser-scanning microscope. Sp1
stainingin CD2-positive cells was quantifiedusing Image J software.
The ratio of Sp1 signal in transduced CD2 positive cells versus non
transduced neighbouring cells was calculated.
Figure 1. Deregulation of the expression of wild-type but not truncated cytoplasmic Sp1 induces apoptosis. (A) Baf-3-Sp1 clone 1 and
(B) Baf-3-Sp1 clone 2 were grown in presence of doxycycline (+ dox) or in absence of doxycycline for the indicated time (- dox). Analysis of Sp1 and
actin protein levels by Western Blot (left panel). Viability measured by flow cytometry after staining with propidium iodide (right panel). (C) Inducible
clone Baf-3-tSp1 was grown with (+ dox) or without (-dox) doxycycline for the indicated time. Analysis of Sp1 and actin protein levels by Western Blot
(left panel). tSp1: truncated Sp1. Cells were costained for DNA (blue) and Sp1 (red) and analysed by confocal microscopy (middle panel). Scale bar
10 mm. Viability measured by flow cytometry after staining with propidium iodide (right panel). Results show the mean 6 sd of 3 independent
experiments.
doi:10.1371/journal.pone.0007035.g001
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RNA extraction and reverse transcription were performed as
previously described [18]. Real Time PCR analysis was carried
out using Platinum SYBR Green qPCR SuperMix UDG kit
(Invitrogen) on an ABI Prism 7700 (Perkin Elmer) [23]. Relative
level of the target sequence against the HPRT reference sequence
was calculated using the DDCt method with calculated real
efficiencies. The sequences of primers used are:
Neo:Forward-ACCAAGGAAGGGGTTGCTA,Reverse-GTTT-
TGAATAGTCACCTGCATCTC;
Cxcl4:F-GCGTCGCTGCGGTGTTTCG,R-ATCCCAGAGG-
AGATGGTCTTCACAC;
Slc39a8:F-TTTCGTGGGACTCGCTATTGGG,R-ATCCA-
CCAAACACAGCAACTGC;
Jun:F-AAGAACTGCATGGACCTAACATTCG,R-GTTAA-
GGAGCACTACAGAAGCAATCTAC;
Gsn:F-AGGTCAAAGGACGCCGTGTAG,R-GCCAGAGC-
CACACCACTGATAG;
Ccnd2:F- TTCATTGAGCACATCCTTCGC,R-AAGTCG-
GTAGCGCACAGAGC;
Ccng2:F-GCCGAGTTGTCTTCTCCAAAGC,R-AAGCAA-
GAGAATTTCCAGCAGTTCC;
Cdkn2c:F-GTCCTTCTGTCAGCCTCCGATG,R-TCGGC-
CATTCTTTAGGGTCCTG;
Human Sp1:F-GCCTCCAGACCATTAACCTCAGT,R-G-
CTCCATGATCACCTGGGGCAT;
Mouse Sp1: F-TCATGGATCTGGTGGTGATGGG,R-G-
CTCTTCCCTCACTGTCTTTGC;
Hprt1:F-TCATTATGCCGAGGATTTGGA,R-CAGAGGG-
CCACAATGTGATG.
Microarray analysis of gene expression
Inducible Baf-3-Sp1 clone 1 was grown in presence or absence
of doxycycline for 28 hrs. Three independent experiments were
performed. RNA extraction, reverse transcription and microarray
hybridization on Affymetrix mouse Genechip Mouse genome 430
2.0 (Affymetrix) were carried out by ProfileXpert (Bron, France).
Absolute expression transcripts levels were normalized for each
chip by globally scaling all probesets to a target signal intensity of
500. Normalized data were analysed using GeneSpring GX 7.3
expression analysis software (Agilent Technology Inc). Differential
probesets expression following Sp1 overexpression relative to
control was determined using GeneSpring GX 7.3 statistical
analysis module ANOVA (1 way test, assuming variance not
equal, FDR 6% with multiple testing correction Benjamini and
Hochberg). 1610 probesets corresponding to 1294 genes with
unique gene symbol identifiers were differentially expressed with a
fold change of expression of 1.3. To identify among deregulated
genes the functional categories linked with Sp1 overexpression,
differentially expressed probesets were imported into Ingenuity
Pathway Analysis (Ingenuity Systems Inc, Mountain View, CA).
The microarray data have been deposited and described in
ArrayExpress under accession number E-MEXP-1702 (http://
www.ebi.ac.uk/microarray-as/ae) in accordance with MIAME
guidelines.
Computational analysis of promoters regions
Promoter sequences (2000 nucleotides upstream of the tran-
scriptional start site) were retrieved using Biomart service of the
Ensembl project. Elkon et al. have shown that 80% of
Transcription Factor-binding sites are located within 1200 bases
upstream of the transcription start site (TSS) [24]. Since there is no
clear consensus for the length of a promoter, we have performed
our analysis studying the 2000 bases upstream of the TSS. Sp1
binding motifs GGGGCGGGG (V$SP1_Q6 as defined by
TRANFAC 7.0) and GG[G/T]G[C/T]GGG [6] and STAT6
binding motif (TTCN4GAA) [25] were searched in promoters
using PATTERNn service (http://bioinfo.hku.hk/services/analyseq/
cgi-bin/patternn_in.pl). We have also used the DiRE server (http://
dire.dcode.org) to identify transcription factor binding sites within
conserved Regulatory Elements (RE) of deregulated genes. A control
list of 1700 probesets was generated randomly that fulfils two criteria:
no change in their expression levels following Sp1 overexpression and
an overall distribution of expression of the control list similar to the
overall distribution of expression of the differentially expressed list
(Figure S2). Two sided binomial tests were conducted in R software to
determine whether there were significant differences in the percentage
of promoters containing transcription factor binding site between the
different gene lists.
Results
Induction of apoptosis by overexpressed Sp1 requires its
binding to DNA
The overexpression of transcription factor Sp1 was achieved
using an inducible Sp1 expression system in untransformed
murine haematopoietic Baf-3 cell line [18]. In Baf-3-Sp1 clone 1
the expression of ectopic full-length wild-type Sp1 was rapidly
induced following doxycycline removal (Figure 1A). The first cells
entering apoptosis were detected 30 hrs after doxycycline removal.
Similar results were obtained when studying a second inducible
clone (Baf-3-Sp1 clone 2) in which induction of Sp1 expression
and apoptosis induction following doxycycline removal are slower
(Figure 1B). In contrast a truncated Sp1 (tSp1, Figure S1), that
accumulates in the cytoplasm does not affect cell viability
(Figure 1C).
We then assessed whether Sp1 requires nuclear localisation
and/or DNA binding to induce apoptosis. Therefore, we have
constructed a retrovirus coding for Sp1 carrying point mutations
on the Zn fingers two and three (Sp1
Zn2,3) that are essential for
DNA binding [1] (Figure S1). Sp1
Zn2,3 does not bind Sp1-binding
consensus sequence in vitro as revealed by EMSA analysis
(Figure 2A). The lack of transactivation potential of Sp1
Zn2,3
mutant was first verified in Drosophila Schneider SL2 cells since
these cells are devoid of Sp-like activities. In SL2 cell line, wild-
type Sp1 transactivates a promoter carrying Sp1 binding sites
confirming that this form is transcriptionally active (Figure 2B). As
expected Sp1
Zn2,3 does not transactivate the same promoter. As
proteins of the Sp/KLF family have nuclear localisation
sequences adjacent to or within the Zn-finger motifs we next
monitored the localisation of transduced Sp1
Zn2,3 protein. Both
Sp1 and Sp1
Zn2,3 are localised in the nucleus of Baf-3 cells
(Figure 2C). The binding of Sp1
Zn2,3 to chromatin was assessed
using triton extraction on live cells [22]. This approach which
allows the removal of soluble proteins but not DNA-associated
proteins was followed by immunostaining of Sp1 to quantify
DNA-bound Sp1. Endogenous and wild-type ectopic Sp1 are
triton-resistant confirming their association with DNA whereas
Sp1
Zn2,3 is triton-soluble suggesting a lack of a strong association
with DNA (Figure 2D). When overexpressed in Baf-3 cells, wild-
type Sp1 induces apoptosis whereas Sp1
Zn2,3 mutant does not
(Figure 2E). Mutations of the Zn finger 2 (Sp1
Zn2), Zn finger 3
(Sp1
Zn3) or the three Zn fingers (Sp1
Zn1,2,3) also abrogate Sp1
ability to induce apoptosis (Figure S3). Altogether, these results
show that induction of apoptosis by Sp1 requires its ability to bind
to DNA through its Zn fingers and suggest that a transcriptional
p r o c e s si si n v o l v e d .
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of Sp1
To have a better insight into the molecular perturbations induced
by Sp1 overexpression, we performed a genome-wide expression
profiling to identify set of genes that are affected by overexpression
of Sp1. Expression profiling was conducted comparing Baf-3-Sp1
clone 1 grown in the presence of doxycycline for 28 hrs as control
and the same clone grown 28 hrs without doxycycline. This time
corresponds to a point where cells already expressed high levels of
Sp1 protein without any detectable cell death (Figure 1A). Three
independent experiments were performed and analysed using the
Affymetrix genechip Mouse genome 430 2.0 arrays (data deposited
in ArrayExpress http://www.ebi.ac.uk/microarray-as/ae, accession
number E-MEXP-1702). Sp1 overexpression was associated with a
substantial modification of transcription profiles (Figure S4).
Differential probesets expression following Sp1 overexpression
relative to control was determined using statistical analysis in
GeneSpring: 1294 genes with unique gene symbol identifiers were
foundtobedifferentiallyexpressedwithafoldchangeofexpressionof
1.3. Among them, the expression of 766 genes was increased whereas
the expression of 528 genes was decreased. With a two-fold change of
expression, 172 genes with unique gene symbol identifiers were found
to be differentially expressed (162 up-regulated genes, 10 down-
regulated genes). Table 1 shows the most up-regulated and down-
regulated genes.Sp1 overexpression has an effect on the expression of
many genes involved in metabolism, ubiquitination and transcription
Figure2. DNA binding deficient Sp1
Zn2,3 does not induce apoptosis. (A) EMSA without (-) or with in vitro produced wild-type human Sp1 (Sp1)
and mutant Sp1 carrying point mutations on Zn fingers 2 and 3 (Sp1
Zn2,3) using
32P-labeled oligonucleotide carrying a Sp1 consensus sequence as a
probe. Arrowhead indicates the DNA-protein complex. (B) Drosophila SL2 cells were transiently co-transfected with luciferase reporter plasmid pGL2
driven by the tata-Sp1 promoter and plasmids pAC encoding wild-type Sp1 or mutated Sp1
Zn2,3. Empty vector was used as control and pPac-EGFP to
normalize the efficiency of transfection. Luciferase activity was assayed 48 hrs after transfection. Results are expressed as relative light units. Results are
the mean 6 sd of triplicate samples and are representative of at least 2 independent experiments. (C) Baf-3 cells were transduced with retroviruses
encoding wild-type Sp1 or Sp1
Zn2,3 and analysed 30 hrs later. Cells were costained for actin (red), Sp1 (green) and DNA (blue) and analysed by confocal
microscopy. Arrowheads indicate cellsoverexpressing Sp1 or Sp1
Zn2,3. Scale bar, 10 mm. (D)Quantificationof DNA-bound Sp1 (Tritonresistant). Twenty-
four hrs post-infection with control, Sp1 or Sp1
Zn2,3 carrying retroviruses, cells were stained for CD2, submitted to extraction with triton to remove
soluble proteins and fixed. Cells were then stained for Sp1. The intensity of Sp1 staining was quantified in transduced CD2-positive cells (n) as well as in
non-transduced neighbouring cells. The ratio of Sp1 signals in transduced versus non-transduced cells is presented. (E) Western blot analysis of Sp1
protein levels in parental Baf-3 cells and in cells transduced with either control, Sp1 or Sp1
Zn2,3 retroviruses purified by magnetic selection with anti-CD2
antibody 30 hrs post-infection (left panel). The percentage of apoptotic cells (Annexin V positive) was measured at various time points among
transduced cells (CD2 positive) by flow cytometry (right panel). Results show the mean 6 sd of 3 independent experiments.
doi:10.1371/journal.pone.0007035.g002
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Functional category Symbol Full name Fold Change UniGene Ensembl Affymetrix ID
Metabolism
Upp1 uridine phosphorylase 1 5,0 Mm.4610 ENSMUSG00000020407 1448562_at
St8sia4 ST8 alpha-N-acetyl-neuraminide
alpha-2,8-sialyltransferase 4
3,6 Mm.306228 ENSMUSG00000040710 1430391_a_at
Galnt3 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3
3,4 Mm.38441 ENSMUSG00000026994 1417588_at
Slc39a8 solute carrier family 39
(metal ion transporter), member 8
3,3 Mm.30239 ENSMUSG00000053897 1416832_at
Tgm2 transglutaminase 2 3,1 Mm.330731 ENSMUSG00000037820 1433428_x_at
Mtap methylthioadenosine phosphorylase 22,1 Mm.28500 ENSMUSG00000062937 1424426_at
Ubiquitin
Arih1 ariadne ubiquitin-conjugating enzyme
E2 binding protein homolog 1
5,5 Mm.305925 1442730_at
Fbxw2 F-box and WD-40 domain protein 2 3,2 1454002_at
Pja2 praja 2 22,0 Mm.41711 ENSMUSG00000024083 1427148_at
Transcription
Jun Jun 3,8 Mm.275071 1417409_at
Irf7 interferon regulatory factor 7 3,5 Mm.3233 ENSMUSG00000025498 1417244_a_at
Bcl9 B-cell CLL/lymphoma 9 22,0 Mm.87600 ENSMUSG00000038256 1451574_at
Sp1 trans-acting transcription factor 1 22,3 Mm.4618 1454852_at
Mecp2 methyl CpG binding protein 2 22,5 Mm.131408 ENSMUSG00000031393 1438930_s_at
Adhesion/Migration
Gsn Gelsolin 6,2 Mm.21109 ENSMUSG00000026879 1437171_x_at
Arl6ip1 ADP-ribosylation factor-like 6
interacting protein 1
5,3 Mm.29924 ENSMUSG00000030654 1423819_s_at
Prickle1 prickle like 1 3,4 Mm.150314 1452249_at
Receptors
/transmembrane
Neo1 neogenin 10,1 Mm.42249 ENSMUSG00000032340 1447693_s_at
Tmem51 transmembrane protein 51 6,5 Mm.27587 ENSMUSG00000040616 1424383_at
Tmem71 transmembrane protein 71 6 Mm.132299 ENSMUSG00000036944 1436212_at
Tnfrsf22 tumor necrosis factor receptor superfamily,
member 22
3,9 Mm.261384 ENSMUSG00000010751
Tmem173 transmembrane protein 173 3,7 Mm.45995 ENSMUSG00000024349 1447621_s_at
Tnfrsf9 tumor necrosis factor receptor superfamily,
member 9
3,4 Mm.244187 ENSMUSG00000028965 1428034_a_at
Clec2d C-type lectin domain family 2,
member d
22,3 Mm.197536 ENSMUSG00000030157 1419477_at
Apoptosis
Bmf Bcl2 modifying factor 4,0 Mm.210125 ENSMUSG00000040093 1454880_s_at
Cell cycle
Lats2 large tumor suppressor 2 3,7 Mm.347899 ENSMUSG00000021959 1439441_x_at
Exocytosis/Trafficking
Stxbp6 syntaxin binding protein 6 (amisyn) 7,4 Mm.285400 1435396_at
Cd74 class II antigen-associated, Ii 3,9 Mm.276499 ENSMUSG00000024610 1425519_a_at
Tcte1l dynein light chain Tctex-type 3 22,0 Mm.29150 ENSMUSG00000031176 1449929_at
Chemokine
Pf4 (Cxcl4) chemokine (C-X-C motif) ligand 4 8,4 Mm.332490 ENSMUSG00000029373 1448995_at
Inflammation
Gbp1 guanylate nucleotide binding protein 1 7,8 Mm.250 ENSMUSG00000028269 1420549_at
Gbp2 guanylate nucleotide binding protein 2 5,1 Mm.24038 ENSMUSG00000028270 1418240_at
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expression of five of the most up-regulated genes (Neo1, Cxcl4, Gsn,
Slc39a8, and Jun) was precisely monitored using quantitative real-time
PCR (Figure 3, left panels). Their up-regulation starts to be detected
16 hrs following doxycycline removal and is also observed in Baf-3
cells transduced with wild-type Sp1 but not Sp1
Zn2,3 indicating that
the binding of Sp1 to DNA is necessary for their induction (Figure 3,
right panels).
Endogenous Sp1 is down-regulated immediately
following Sp1 overexpression
Oneofthemost down-regulatedgene followingoverexpression of
human Sp1 is the endogenous murine sp1 gene (2.3-fold decrease,
Table 1). Sp1 promoter contains Sp1 binding sites and the Sp1
protein has been shown to autoregulates its own expression [26]. As
Baf-3-Sp1 clone 1 expresses human Sp1 as well as GFP under the
sameinduciblepromoterwecould monitor,inparallel,GFP protein
expression by flow cytometry and both endogenous murine and
ectopic human Sp1 mRNA levels by real-time PCR. Kinetic studies
showed that the first GFP expressing cells are detected 8 hrs after
doxycycline removal (Figure 4A). This correlates with the
expression of ectopic Sp1 at the mRNA and protein levels
(Figure 4B and data not shown). Importantly, down-regulation of
endogenous sp1 gene transcription starts to be observed as early as
8 hrs after doxycycline removal in the whole cell population where
only 20% of the cells are GFP positive (Figure 4C). This down-
regulation requires the binding of Sp1 to the DNA. Altogether these
results indicate that an excess of DNA-bound Sp1 is sensed by cells
and induces a rapid repression of endogenous sp1 gene expression,
revealing a transcriptional negative feedback loop.
Genes with Sp1 consensus binding site in their
promoters are enriched among down-regulated genes
but not among up-regulated genes
We next determined whether the set of Sp1-modified genes was
enriched for the presence of Sp1 binding motif in their promoters
(consensus Sp1 binding motif GGGGCGGGG as defined by
TRANFAC 7.0 (V$SP1_Q6) and its variant GG[G/T]G[C/
T]GGG [6]). As a control, we also estimated the degree of enrichment
for STAT6 transcription factor binding site TTCN4GAA [25]. The
presence of Sp1 and STAT6 binding sites was searched using a
computational approach in the promoter regions consisting of
2000 bp upstream from the transcription start site. As a control, we
analysed the promoters of a control list generated randomly that fulfils
two criteria: no change in the gene expression levels following Sp1
overexpression and an overall distribution of expression that is similar
to the one of the differentially expressed list (Figure S2). There was no
significant difference in the percentage of promoters containing
STAT6 site among down or up-regulated and control genes. In
contrast, Sp1 sites were enriched among the promoters of genes whose
expression was repressed (Table 2). Moreover, down-regulated genes
contain on average more Sp1 sites in their promoters than genes from
the control list. Surprisingly, there was no enrichment for the presence
of Sp1 sites among the genes whose expression was increased by Sp1.
Functional category Symbol Full name Fold Change UniGene Ensembl Affymetrix ID
Serpinf1 serine (or cysteine) peptidase inhibitor,
clade F, member 1
4,3 Mm.2044 ENSMUSG00000000753 1416168_at
Signal transduction
Pik3r3 phosphatidylinositol 3 kinase,
regulatory subunit, polypeptide 3 (p55)
5,9 Mm.253819 ENSMUSG00000028698 1456482_at
Eps8 epidermal growth factor
receptor pathway substrate 8
3,4 Mm.235346 ENSMUSG00000015766 1422824_s_at
Ppp3cb protein phosphatase 3, catalytic subunit,
beta isoform
22,1 Mm.274432 ENSMUSG00000021816 1433835_at
Misclaneous
Hist2h2aa2 histone cluster 2, H2aa2 11,0 1438815_at
E230032D23Rik E230032D23Rik 6,5 Mm.387210 1444420_at
4933411B09Rik 4933411B09Rik 4,7 1430863_at
4,2 1443777_at
RNAse k ribonuclease, RNase K 4,0 Mm.29852 ENSMUSG00000040904 1442441_at
Ccdc19 coiled-coil domain containing 19 3,6 Mm.78373 ENSMUSG00000026546 1429930_at
3110040M04Rik 3110040M04Rik 3,5 Mm.359303 1429700_at
3,5 Mm.75540 1447844_at
Calml4 calmodulin-like 4 3,4 Mm.28623 ENSMUSG00000032246 1424713_at
4930513N10Rik 4930513N10Rik 3,2 Mm.386996 1457415_a_at
Scoc short coiled-coil protein 22,0 Mm.379079 ENSMUSG00000063253 1416267_at
Morc3 microrchidia 3 22,1 Mm.287329 ENSMUSG00000039456 1452224_at
Hba-a1 hemoglobin alpha, adult chain 1 22,3 Mm.196110 ENSMUSG00000069917 1452757_s_at
Genes identified by microarray analysis (Affymetrix GeneChip Microarray 430.2) as most up-regulated or down-regulated following ectopic Sp1 expression in Baf-Sp1
clone 1 (3 independent experiments). Differential gene expression following Sp1 deregulation relative to control was determined using GeneSpring GX 7.3 statistical
analysis module ANOVA. The full list of deregulated genes following Sp1 overexpression with informations on each gene (ID, Gene Ontology, Kegg pathway, probeset
quality, mean expression, mean deregulation) can be found at ftp://pbil.univ-lyon1.fr/pub/datasets/DeniaudE2009/.
doi:10.1371/journal.pone.0007035.t001
Table 1. Cont.
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DiRE that predicts regulatory elements (RE) within the promoters of a
set of genes based on their inter-species conservation and their
transcription factor binding sites content. Again the percentage of
candidate regulatory elements containing a Sp1 binding site was
higher within down-regulated genes compared to a control list (Figure
S5) and Sp1 was predicted to be the most important transcription
factor within the promoters of down-regulated genes. When the
analysis was extended to promoters and the most conserved
Evolutionary Conserved Regions (ECRs), Sp1 occurrence was the
highest among down-regulated genes. Altogether, these analysis
indicate Sp1-binding sites are enriched only in down-regulated genes
but not in up-regulated genes. This suggests that down-regulation of
gene expression could be directly mediated by Sp1 whereas up-
regulation of gene expression does not seem to involve the association
of Sp1 with proximal promoters. As Sp1 DNA-binding is necessary for
deregulation of gene expression, up-regulation of gene expression
could represent an indirect event of Sp1 binding to genomic DNA.
Deregulated expression of cell cycle regulating genes
following Sp1 overexpression is associated with
accumulation of cells in the G1 phase of the cell cycle
Among the genes found to be differentially expressed, using the
Ingenuity Pathway Analysis software, we observed the highest
enrichments for the following categories: cancer, cell death and
cell cycle (Figure S6). The list of genes belonging to these 3
categories being very large, we focused our attention on the cell
cycle category as only a very small number of genes involved in the
core cell cycle machinery was found to be affected by Sp1
overexpression (Figure 5). As a matter of fact, microarray data
indicated that among the genes associated with the progression
through the cell cycle such as cyclins, cyclin-dependent protein
kinases and cyclin-dependent kinase inhibitors, only three showed
a significant modification of expression levels: Ccnd2 (cyclin D2,
1.7-fold decrease), Ccng2 (cyclin G2, 1.9-fold increase) and Cdkn2c
(cyclin-dependent kinase inhibitor 2c/p18, 2.0-fold increase). The
down-regulation of Ccnd2 expression and the up-regulation of
Ccng2 and Cdkn2c expression can be observed 16 hrs after
doxycycline removal in inducible Baf-3-Sp1 clone (Figure 6A)
and require Sp1 binding to DNA (Figure 6B). These genes have all
been involved in the regulation of the G1-S transition. Therefore,
we next investigated whether Sp1-induced overexpression of these
genes could impair cell proliferation. Baf-3-Sp1 clone 1 was grown
in the absence or in the presence of doxycycline and the
distribution of the cells through the different phases of the cell
cycle was studied by flow cytometry after a pulse with BrdU. As
soon as 22 hrs after Sp1 induction the percentage of cells in the G1
phase started to increase whereas the percentage of cells in the S
phase decreased in comparison to control condition (Figure 7A). A
more pronounced effect on cell cycle was observed 28 hrs after
Figure 3. Changes in expression profile is dependent on Sp1 binding to DNA. Kinetic of expression levels of five differentially expressed
genes (Neogenin, Slc39a8, Gelsolin, Cxcl4, Jun) following doxycycline removal in Baf-3-Sp1 clone 1 (left panel). At the indicated times, cells were
harvested and mRNA levels were measured by real-time PCR and normalized to HPRT mRNA levels. Results show the ratio of the mRNA levels
measured in the absence of doxycycline relative to mRNA levels measured in the presence of doxycycline at each time point. Results show the mean
6 sd of at least 2 independent experiments. Expression levels in Baf-3 cells transduced with either control, Sp1 or Sp1
Zn2,3 retroviruses purified by
magnetic selection with anti-CD2 antibody 30 hrs post-infection (right panel). Results show the mean 6 sd of at least 2 independent experiments.
doi:10.1371/journal.pone.0007035.g003
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2 (Figure 7B) and in parental Baf-3 cells transduced with wild-type
Sp1 (Figure 7C). Cell cycle was not affected by the accumulation
of truncated tSp1 in the cytoplasm of the cells (Figure 7D) or by
the expression of Sp1
Zn2,3 (Figure 7E). A detailed analysis of the
cell cycle progression indicates that Sp1 overexpression only delays
progression from the G1 to the S phase (data not shown). The
results indicates that Sp1 overexpression leads to the expression of
cell cycle inhibitor Cdkn2c and stress-associated cyclin G2,
whereas the expression of cell cycle regulating cyclin D2 is
down-regulated and this correlates with the inhibition of G1/S
transition of cycling cells, a process that precedes the onset of cell
death.
Discussion
This study extends previous findings that have shown that Sp1
overexpression is detrimental to untransformed cells [18,19]. Our
study shows that overexpressed Sp1 induces an inhibition of the
progression through the cell cycle of Baf-3 cells that precedes
apoptosis. Both processes require the binding of Sp1 to DNA and
are not observed following the expression of a cytoplasmic
truncated form of Sp1 or a mutated Sp1 unable to bind DNA.
Microarray analysis shows that among the genes found to be
differentially expressed following Sp1 overexpression there is an
enrichment in genes involved in cancer, cell cycle and cell death.
Indeed,analysisofSp1-induced deregulated geneswith Ingenuity
Pathways Analysis software revealed that 223 of them are linked
with apoptosis. This includes the up-regulation of proteins that
induce apoptosis when overexpressed such as pro-apoptotic Bcl-2
family members (Bmf, Bcl2L11/Bim, Bcl2L13/Rambo) [27],
caspase 6 [28], cell death inducing factors (CIDEB, DAP) [29,30],
dependence receptor neogenin [31] (Table 1 and microarray data
available in Array express). Therefore Sp1 overexpression could
trigger apoptosis through one or a combination of these pathways.
A number of data support a link between Sp1 and cell cycle
progression [16,32]. A computational approach by Elkon et al.
comparing the promoters of a set of cell cycle regulated genes
revealed that Sp1 binding sequences are significantly enriched in
promotersofgenesthatareexpressedinG1/Sphase[24].Although
Sp1 has been linked with cell growth, both positive and negative
effects of Sp1 on cell growth have been reported. This is consistent
with the regulation of both growth promoting genes as well as
growth inhibitory genes by Sp1 [16]. Although down-regulation of
cell cycle inhibitor cdkn1a/p21 has been implicated in Sp1-induced
inhibition of proliferation in vascular smooth muscle cells [19], we
did not find a significant modification of cdkn1a gene expression
upon Sp1 induction in Baf-3 cells (Figure 5). However, we identified
cyclin D2, cyclin G2 and cdkn2c/p18 as being deregulated among cell
cycle regulating genes following the binding to DNA of overex-
pressed Sp1. The products of these genes could be responsible for
Sp1-mediated cell cycle inhibition that we observed as they are all
involved in regulating G1/S progression. D-cyclins are believed to
serve as a link between the extracellular environment and the cell
cycle machinery,drivingprogression throughtheG1/S phaseofthe
cell cycle. In Baf-3 cells, Interleukin-3 removal induces a decrease of
cyclin D2 mRNA expression and a cell cycle arrest that can be
abolished by ectopic expression of cyclin D2 [33]. Cdkn2c is a
member of the INK4 family that block cell cycle progression by
bindingto cyclin dependent kinaseCdk4 or Cdk6 and inhibiting the
action of cyclin D. Finally, cyclin G2 is an unconventional cyclin
that is up-regulated in B cells responding to growth inhibitory
signals and its overexpression promotes a cell cycle arrest in G1
phase [34,35]. These 3 genes have previously been shown to possess
Sp1-binding sites in their promoters and/or to be regulated by Sp1
[36–38]. In our experimental system, regulation of these cell cycle
genes are likely a direct consequence of Sp1 on transcription.
This study revealed that elevation of Sp1 levels is almost
immediately followed by a decrease of sp1 gene transcription. As a
matter of fact, endogenous Sp1 mRNA levels start to decrease as
soon as 8 hrs after doxycycline removal. At this time point, only
20% of the cells are GFP positive and ectopic Sp1 mRNA starts to
be detected in the whole population cell lysate. Transient
transfections of Sp1 and luciferase assays using a minimal Sp1
promoter have revealed that Sp1 autoregulates positively its own
transcription [26]. Our results confirm that Sp1 autoregulates its
own transcription and that an excess of DNA-bound Sp1 represses
sp1 gene transcription in the chromatin context.
The genome-wide expression profiling in Baf-3 cells indicates
that a substantial proportion of expressed genes shows a
modification of their transcription following Sp1 deregulation.
Using real-time PCR, we have confirmed the impact of Sp1 on the
expression of 18 out of 18 of these genes and shown that it requires
Figure 4. Sp1 autoregulates negatively its transcription. (A) Baf-
Sp1 clone 1 was grown in the absence of doxycycline. At the indicated
times the percentage of GFP expressing cells was measured by Flow
cytometry. (B) & (C) mRNA levels of ectopic human Sp1 and
endogenous murine Sp1 mRNA levels measured as indicated in
figure 3. Results show the ratio of the mRNA levels measured in Sp1-
overexpressing cells relative to mRNA levels measured in control cells
and show the mean 6 sd of at least 2 independent experiments.
doi:10.1371/journal.pone.0007035.g004
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and Cyclin-dependent kinases inhibitors expression in Sp1 overexpressing cells compared to non expressing cells. Expression ratios are from
microarray data (GeneSpring GX).
doi:10.1371/journal.pone.0007035.g005
Table 2. Frequency of Sp1 consensus binding sites in the promoters of genes deregulated by Sp1.
Sp1 site: GGGGCGGGG
Percentage of genes with binding sites p-value
(d) Number of binding sites per gene p-value
(d)
control list
(a) 15.1% 1.3
up-regulated genes
(b) 12.4% 0.0715 1.2 0.2585
down-regulated genes
(c) 20.3% 0.0031 1.7 0.0001
Variants of Sp1 site: GG[G/T]G[C/T]GGG
Percentage of genes with binding sites p-value
(d) Number of binding sites per gene p-value
(d)
control list
(a) 39.4% 1.7
up-regulated genes
(b) 41.3% 0.3591 1.7 0.82
down-regulated genes
(c) 47.5% 0.0005 2 0.0004
STAT6 site: TTCNNNNGAA
Percentage of genes with binding sites p-value
(d) Number of binding sites per gene p-value
(d)
control list
(a) 41.4% 1.4
up-regulated genes
(b) 40.0% 0.5028 1.3 1
down-regulated genes
(c) 36.9% 0.0549 1.3 0.1694
Transcription factor binding sites were searched among the first 2000 nucleotides of the promoter region of differentially expressed genes and non-regulated genes
using PATTERNn service. Sp1 binding motifs: GGGGCGGGG and GG[G/T]G[C/T]GGG. STAT6 binding motif: TTCN4GAA.
(a)Control list of non-regulated genes generated randomly as described in the experimental procedures.
(b)Up-regulated genes from differentially expressed gene list (.1.3 fold).
(c)Down-regulated genes from differentially expressed gene list (,1.3 fold).
(d)Statistical significance calculated as described in the experimental procedures. P-values are the comparison of up-regulated vs control and down-regulated vs control.
doi:10.1371/journal.pone.0007035.t002
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determine the proportion of genes that were potentially tran-
scribed via binding of Sp1 to their promoter, we have search for
Sp1-binding sites in the promoter of regulated genes. We observe
that only down-regulated genes show a significant enrichment for
Sp1 sites in their promoters. It is unlikely that this inhibition is due
to the squelching of factors required for transcription as there is no
global shut-down of transcription following Sp1 overexpression.
Moreover expression of high levels of mutant nuclear form of Sp1
does not lead to transcription modulation. Therefore our results
suggest that overexpressed DNA-bound Sp1 exerts a specific
inhibitory effect on Sp1-driven transcription in Baf-3 cells.
Contrasting with Sp1, the genes induced by c-Rel deregulation
show an enrichment for genes containing consensus NF-kB/Rel
sites in their proximal promoter region [39]. However, the up-
regulation of a large number of genes following Sp1 overexpres-
sion could result from an indirect process that requires the binding
of Sp1 to DNA. Indeed, DNA-binding of Sp1 could trigger
transcription through multiple mechanisms. First, Sp1 could
induce the expression of transcription factors that would then
activate transcription. This seems unlikely since promoters of up-
regulated genes did not exhibit an enrichment for binding sites for
the few transcription factors (c-jun, Fos, E2F2) that were up-
regulated by Sp1 (data not shown). Moreover, the DiRE analysis
does not reveal an enrichment of putative regulatory elements in
the non-coding sequence of deregulated genes (Figure S5). Second,
Sp1 might affect gene transcription through the control of non
coding RNA as it was observed that many Sp1 binding sites are
localised next to non coding RNA genes [6]. Finally, the human
genome contains more than 12,000 occupied Sp1 binding sites [6]
and Sp1 has also been shown to localize within subnuclear foci
that infrequently overlap with sites of transcription [40].
Therefore, the association of deregulated Sp1 with DNA might
perturb chromatin structure. Further experiments will be neces-
sary to determine the precise mechanisms involved in the gene
transcription up-regulation induced by overexpressed Sp1.
Deregulated expression of Sp1 has been associated with the late
steps of cell transformation [14–16]. Analysis of the categories of
genes enriched following Sp1 deregulation revealed that the highest
enrichment was observed for genes belonging to the Cancer
category (Figure S6). The expression of genes known to have
important role in migration/metastasis were up-regulated following
Sp1 overexpression. This includes actin-binding protein gelsolin a
protein involved incell motility and required forcancercell invasion
[41], matrix metalloproteases MMP9 which degrade extracellular
matrix and promotes invasion [42], metastasis-associated proteins
S100A4/metastasin [43] and cathepsin B [44] (data not shown).
Altogether these results show that Sp1 overexpression is detrimental
for untransformed cells. However, in cells having acquired
resistance to cell cycle inhibition and cell death, expression of these
genes involved in migration/metastasis could confer a selective
advantage and contribute to their further transformation.
Supporting Information
Figure S1 Sp1 constructs used in the study. Wild-type of Sp1
(Sp1) consists of four transactivation domains (A to D) and a DNA-
binding domain (DBD) composed of three Zinc fingers. The
mutant form Sp1Zn2,3 carries point mutation on the second and
third Zinc fingers of the DBD. The truncated Sp1 tSp1 is
composed of the first 418 amino acids.
Found at: doi:10.1371/journal.pone.0007035.s001 (0.28 MB EPS)
Figure S2 Distribution of the expression of the genes differen-
tially expressed following Sp1 deregulation (1610 probesets) (A)
and the non-regulated genes from a control list (1700 probesets) (B)
generated as indicated in the experimental procedures.
Found at: doi:10.1371/journal.pone.0007035.s002 (0.38 MB EPS)
Figure S3 Zn finger mutations abolish Sp1 ability to induce
apoptosis. Baf-3 cells were transduced with retroviruses encoding
wild-type Sp1 (Sp1) or Sp1 mutants carrying mutations in their
DNA binding domain and analysed 30 hrs later. (A) Cells were
costained for actin (red), Sp1 (green) and DNA (blue) and analysed
by confocal microscopy. Arrowheads indicate overexpressing cells.
Scale bar, 10 mm. (B) Left Western blot analysis of Sp1 protein
levels in Baf-3 cells transduced with either control, Sp1 or various
Sp1Zn mutants retroviruses purified with anti-CD2 antibody
30 hrs post-infection. Right The percentage of apoptotic cells
(Annexin V positive) was measured at various time points among
infected cells (CD2 positive) by flow cytometry. Results show the
mean 6 sd of at least 2 independent experiments.
Found at: doi:10.1371/journal.pone.0007035.s003 (0.77 MB EPS)
Figure S4 Gene expression profiles following Sp1 overexpres-
sion. Scatter plots of the mean signal intensity values of three
independent microarray experiments (Affymetrix Mouse Genome
Figure 6. Changes in expression profile of cyclin D2, cdkn2c/
p18 and cyclin G2. mRNA levels of cyclin D2, cdkn2c and cyclin G2 in
Baf-3-Sp1 clone 1 (A) or in Baf-3 cells transduced with control, Sp1 and
Sp1
Zn2,3 encoding retroviruses (B) were measured by real-time PCR as
indicated in figure 3. Results show the ratio of the mRNA levels
measured in Sp1-overexpressing cells relative to mRNA levels measured
in control cells and show the means of 6 sd of at least 2 independent
experiments.
doi:10.1371/journal.pone.0007035.g006
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analysis software (Agilent Technology Inc). (A) All probesets. (B)
Probesets differentially expressed following Sp1 overexpression
relative to control. Differential expression was determined using
GeneSpring GX 7.3 statistical analysis module ANOVA 1 way
test, assuming variance not equal, choosing a false discovery rate of
6% with multiple testing correction (Benjamini and Hochberg).
This gave a list of 1610 differentially expressed probesets with a
fold change of expression of 1.3.
Found at: doi:10.1371/journal.pone.0007035.s004 (0.44 MB EPS)
Figure S5 Analysis of transcription factor binding sites within
Regulatory Elements (RE), predicted using inter-species conservation,
of (A) down-regulaled genes,(B) up-regulatedgenes and (C)the control
list (expressed but non- regulated). Search was performed via the
DiRE server which uses RE located within as well outside promoters
(http://dire.dcode.org, Gotea, V. and I. Ovcharenko (2008) DiRE:
identifying distant regulatory elements of co-expressed genes. Nucleic
Acids Research, doi:10.1093/nar/gkn300). The results show the
occurence of transcription factor binding sites within RE and the
Importance of each transcription factor that is the product of its
occurrence and its weight (i.e. its association with the input gene set).
The number of genes eligible for DiRE analysis are indicated.
Found at: doi:10.1371/journal.pone.0007035.s005 (0.36 MB EPS)
Figure S6 Functional classification of differentially expressed
genes following Sp1 overexpression. Functional classification was
performed using the Ingenuity Pathway Analysis software. Among
the genes found to be differentially expressed with a fold change of
expression of 1.3, 732 genes were eligible for function/pathway
analysis. The seven highest-ranking functional categories are
shown. The scores are based on their connectivity.
Found at: doi:10.1371/journal.pone.0007035.s006 (0.34 MB EPS)
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